





Solutions in Sight®

Q1 FY23 Earnings Presentation January 31, 2023

Forward Looking Statements / Non-GAAP Measures



Forward Looking Statements

Certain statements in this supplement contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward looking statements include statements concerning unaudited financial results; Q2 FY23 revenue and earnings guidance; industry or market outlook; addressable market; growth drivers; trends; market size; customer demand; product volumes, synergies; expected future financial results and performance; and any statements using the terms "believe," "expect," "intend," "outlook," "future," "anticipate," "will," "could," "estimate," "guidance," or similar statements.

These forward-looking statements involve risks and uncertainties that could cause Varex's actual results to differ materially from those anticipated. While forward-looking statements are based on assumptions and analyses made by Varex and its management that we believe to be reasonable under the circumstances, whether actual results and developments will meet our expectations and predictions depend on a number of risks, uncertainties, and other factors discussed in our most recently filed Annual Report on Form 10-K, in our other public filings and press releases, and on our website. These risks, uncertainties, and other factors include supply chain and logistical challenges; price increases from suppliers and service providers and inflation generally; the severity and duration of the COVID-19 pandemic and its impact on both the global economy and Varex's business; shifts in product mix; the continued impact of tariffs or a global trade war on our products and customer purchasing patterns; economic and political conditions globally or regionally, including any impact due to armed conflicts (such as the recent conflict between Russia and Ukraine as well as governmental sanctions imposed in response); demand for and delays in delivery of products of Varex or its customers; litigation costs; Varex's ability to develop, commercialize and deploy new products; the impact of reduced or limited demand by purchasers of certain X-ray products; and the impact of competitive products and pricing; and the other risks listed from time to time in our filings with the U.S. Securities and Exchange Commission, which by this reference are incorporated herein.

Any forward-looking statements made in this supplement speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. The company assumes no obligation to update or revise the forward-looking statements in this presentation because of new information, future events, or otherwise.

Non-GAAP Measures

Certain information provided in this presentation includes financial measurements that are not required by, or presented in accordance with, generally accepted accounting principles (GAAP). These non-GAAP measures, such as non-GAAP gross margin, non-GAAP operating expense, non-GAAP operating margin, and non-GAAP net earnings per diluted share, should not be considered as alternatives to GAAP measures and may be calculated differently from, and therefore may not be comparable to, similarly titled measures used at other companies. For a reconciliation to the most directly comparable GAAP financial measures, please refer to Varex's Q1FY23 earnings release at www.vareximaging.com and the reconciliation contained at the end of this presentation.

Q1 FY23 Results

Revenue \$206M

Non-GAAP Gross Margin* 32% Non-GAAP EPS* \$0.21 Cash, Cash Equiv., & Mkt. Sec.** \$108M

- > Demand as expected during the quarter
- > Supply chain more in balance with demand
- > Product mix pressured margins





^{**} Cash & cash equivalents (\$82M) + Marketable securities (\$19M) + CDs (\$7M).





Q1 FY23 Sequential Performance














Note: \$millions except for per share data

Demand Environment


СТ	
Fluoroscopy	
Oncology	
Dental	0

Mammography	
Radiography & Others	
Industrial	




^{*} Based on 1Q23 sales compared to five quarter average trend

Q1 FY23 Revenue Details




Revenue, \$M	Q1 23	Q4 22	Q3 22	Q2 22	Q1 22
Medical	160	181	167	170	156
Industrial	46	50	47	44	43



Revenue, \$M	Q1 23	Q4 22	Q3 22	Q2 22	Q1 22
Americas	75	80	64	68	61
EMEA	64	74	70	70	67
APAC	67	77	80	77	71

Quarterly Results - GAAP

\$ in Millions, except per share data	Q1 FY23	Q4 FY22	Q1 FY22
Revenue	\$206	\$231	\$199
Gross Margin	31%	32%	33%
Operating Expenses	\$50 24%	\$50 22%	\$51 26%
Operating Income	\$13 6%	\$25 11%	\$14 7%
Net Earnings	\$3	\$13	\$1
EPS, diluted Avg. shares, diluted	\$0.08 40.6	\$0.32 40.9	\$0.03 43.9



Quarterly results – Non-GAAP*

\$ in Millions, except per share data	Q1 FY23	Q4 FY22	Q1 FY22
Revenue	\$206	\$231	\$199
Gross Margin (Non-GAAP)	32%	33%	34%
Operating Expenses (Non-GAAP)	\$47 23%	\$47 20%	\$44 22%
Operating Income (Non-GAAP)	\$18 9%	\$29 13%	\$23 11%
Net Earnings (Non-GAAP)	\$8	\$17	\$10
EPS, diluted (Non-GAAP) Avg. shares, diluted	\$0.21 40.6	\$0.42 40.4	\$0.25 41.4



Select Balance Sheet Data

\$ in Millions	Q1 FY23	Q4 FY22	Q1 FY22
Assets			
Cash, Cash Equiv. and Mkt. Sec.	\$108	\$113	\$158
Accounts Receivable, net	\$158	\$173	\$127
Inventories	\$320	\$303	\$248
Total Assets	\$1,181	\$1,184	\$1,139
Liabilities			
Accounts Payable	\$86	\$78	\$72
Debt, net	\$443	\$414	\$437
Total Liabilities & Equity	\$1,181	\$1,184	\$1,139

Working Capital Performance	Q1 FY23	Q4 FY22	Q1 FY22
DSO (in days)	70	68	58
DOI	203	176	168
DPO	55	45	49




Select Debt and Cash Flow Data

\$ in Millions	Q1 FY23	Q4 FY22	Q1 FY22
Debt			
Gross Debt (Ratings: Moody's B2 / S&P B+)	\$450	\$450	\$480
Net Debt ¹	\$342	\$337	\$322
Adjusted EBITDA ²			
Adjusted EBITDA	\$25	\$36	\$30
Cash Performance			
Cash Flow from Operations	(\$4)	\$17	\$11
Capital Expenditures	(\$6)	(\$10)	(\$4)
Cash Interest	(\$14)	\$0	(\$15)
Cash Taxes	(\$5)	(\$3)	\$0
Net Change in Cash	(\$8)	(\$10)	\$13

¹Net Debt is defined as gross debt less cash & cash equivalents, marketable securities and CDs.

²Adjusted EBITDA is defined as non-GAAP net earnings plus non-GAAP interest expense, non-GAAP taxes, non-GAAP depreciation, non-GAAP amortization and stock-based compensation



Outlook Q2 FY23

Guidance	Non-GAAP
Revenues, \$M	\$205 - \$225
EPS Per Diluted Share	\$0.05 - \$0.25
Assumptions	Non-GAAP
Assumptions Gross Margin	Non-GAAP 31% - 32%







VAREX I M A G I N G

Solutions in Sight®

Q & A







Solutions in Sight®

Non – GAAP Reconciliation

(In millions, except per share amounts)

GROSS PROFIT RECONCILIATION

Revenues, net

Gross profit

Amortization of intangible assets

Non-GAAP gross profit

Gross margin %

Non-GAAP gross margin %

Three Months Ended				
December 30, 2022		De	ecember 31, 2021	
\$	205.6	\$	198.8	
\$	63.3	\$	64.8	
	1.8		1.8	
\$	65.1	\$	66.6	
	30.8 %		32.6 %	
	31.7 %		33.5 %	



SELLING, GENERAL AND ADMINISTRATIVE EXPENSE RECONCILIATION

Selling, general and administrative

Amortization of intangible assets

Restructuring charges

Other non-operational costs

Non-GAAP selling, general and administrative expense

OPERATING EXPENSE RECONCILIATION

Other expense, net

Amortization of intangible assets

Restructuring charges

Other non-operational costs

Non-GAAP operating expense

Three Months Ended						
December 30, 2022		December 31 2021				
\$	30.3	\$	33.1			
	1.6		1.9			
	0.7		3.2			
	0.6		1.8			
\$	27.4	\$	26.2			
\$	50.3	\$	50.8			
	1.6		1.9			
	0.7		3.2			
	0.6		1.8			
\$	47.4	\$	43.9			



OPERATING INCOME RECONCILIATION

Operating income

Amortization of intangible assets (includes amortization impacts to cost of revenues)

Restructuring charges (includes restructuring impact to cost of revenues)

Other non-operational costs (includes other non-operational impacts to cost of revenues)

Total operating income adjustments

Non-GAAP operating income (loss)

Operating margin

Non-GAAP operating margin

Three Months Ended							
Dec	ember 30, 2022	December 31, 2021					
\$	13.0	\$	14.0				
	3.4		3.7				
	0.7		3.2				
	0.6		1.8				
\$	4.7	\$	8.7				
\$	17.7	\$	22.7				
	6.3 %		7.0 %				
	8.6 %		11.4 %				



Three Months Ended

(In millions, except per share amounts)	Dec	ember 30, 2022	Dec	ember 31, 2021
INCOME (LOSS) BEFORE TAXES RECONCILIATION	<u> </u>	F 4	· 	0.0
Income (loss) before taxes	\$	5.4	\$	3.3
Total operating earnings adjustments		4.7		8.7
Convertible notes non-cash interest expense				2.1
Total income before tax adjustments	\$	4.7	\$	10.8
Non-GAAP income (loss) before taxes	\$	10.1	\$	14.1
INCOME TAX EXPENSE RECONCILIATION				
Income tax expense	\$	2.2	\$	1.7
Tax effect on non-GAAP adjustments		0.7		(1.8)
Non-GAAP income tax expense	\$	1.5	\$	3.5
NET INCOME (LOSS) AND DILUTED NET INCOME (LOSS) PER SHARE RECONCILIATION				
Net income (loss) attributable to Varex	\$ \$	3.1	\$	1.4
Total earnings before taxes adjustments	\$	4.7	\$	10.8
Effective tax rate on non-GAAP adjustments		(14.9)%		16.7 %
Tax effect on non-GAAP adjustments	\$	0.7	\$	(1.8)
Non-GAAP net income (loss)	\$ \$ \$	8.5	\$	10.4
Diluted net income (loss) per share	\$	0.08	\$	0.03
Non-GAAP diluted net income (loss) per share	\$	0.21	\$	0.25



(In millions, except per share amoun	(In	millions.	except	per share	amounts
--------------------------------------	-----	-----------	--------	-----------	---------

DILUTED WEIGHTED AVERAGE SHARES OUTSTANDING RECONCILIATION

GAAP weighted average common shares - dilutive
Dilution offset from convertible notes hedge transaction
Dilutive shares not included for GAAP due to net loss
Non-GAAP dilutive shares

ADJUSTED EBITDA RECONCILIATION

Net income (loss) attributable to Varex

Interest expense
Income tax expense
Depreciation
Amortization

Stock based compensation

Restructuring charges

Other non-operational costs

Adjusted EBITDA

Three Months Ended					
December 2022	r 30,		ember 31, 2021		
	40.6		43.9		
	_		(2.5)		
	40.6		41.4		
\$	3.1	\$	1.4		
	7.5		9.9		
	2.2		1.7		
	4.6		4.8		
	3.4		3.8		
	3.3		3.4		
	0.7		3.2		
	0.6		1.8		
\$	25.4	\$	30.0		



Effect of Convertible Note Hedge and Warrants on Non-GAAP Diluted Share count

Impact of Warrants and Convertible Note Hedge at Various Share Prices Shares added back for non-GAAP related to convertible Impact of Warrants on GAAP note hedge						
Share Price*	Diluted Shares	Non-GAAP Diluted Shares				
\$20.00	_	<u> </u>				
\$20.81						
\$21.00	-	85,790				
\$22.00		518,691				
\$23.00	_	913,948				
\$24.00		1,276,267				
\$24.98	_	1,601,592				
\$25.00	9,610	1,609,600				
\$26.00	378,840	1,917,292				
\$27.00	720,720	2,202,193				
\$28.00	1,038,180	2,466,743				
\$29.00	1,333,746	2,713,048				
\$30.00	1,609,608	2,942,933				
\$31.00	1,867,672	3,157,987				
\$32.00	2,109,608	3,359,600				
\$33.00	2,336,880	3,548,994				
\$34.00	2,550,784	3,727,247				
\$35.00	2,752,464	3,895,314				



Illustrative Impact of ASU 2020-06



Quarterly ASU 2020-06 Share Count Illustration						
GAAP			NON-GAAP*			
Net Income before effect of Convertible Notes (\$M)	Add-back of After-tax Interest Expense	Incremental Dilutive Shares for EPS Calculation	Net Income before effect of Convertible Notes (\$M)	Add-back of After-tax Interest Expense	Incremental Dilutive Shares for EPS Calculation	
\$1	\$0.0	0	\$4	\$0.0	0	
\$4	\$0.0	0	\$7	\$0.0	0	
\$5	\$0.0	0	\$8	\$0.0	0	
\$6	\$1.4	9	\$9	\$1.4	9	
\$7	\$1.4	9	\$10	\$1.4	9	
\$8	\$1.4	9	\$11	\$1.4	9	
\$9	\$1.4	9	\$12	\$1.4	9	
\$10 and above	\$1.4	9	\$13	\$1.4	9	

Annual ASU 2020-06 Share Count Illustration						
GAAP			NON-GAAP*			
Net Income before effect of Convertible Notes (\$M)	Add-back of After-tax Interest Expense	Incremental Dilutive Shares for EPS Calculation	Net Income before effect of Convertible Notes (\$M)	Add-back of After-tax Interest Expense	Incremental Dilutive Shares for EPS Calculation	
\$0	\$0.0	0	\$14	\$0.0	0	
\$10	\$0.0	0	\$24	\$0.0	0	
\$20	\$0.0	0	\$34	\$0.0	0	
\$30	\$5.6	9	\$44	\$5.6	9	
\$40	\$5.6	9	\$54	\$5.6	9	
\$50 and above	\$5.6	9	\$64	\$5.6	9	

Note: The table above assumes 41 million diluted shares for GAAP earnings per share as a starting point and various other estimates. The tables above are illustrative only and actual results may differ from those presented above.

^{*} Non-GAAP shares include the benefit of call option issued by the company in association with its convertible notes issued June 2020

Discussion of Non – GAAP Financial Measures

This presentation includes non-GAAP financial measures derived from our Condensed Consolidated Statements of Operations. These measures are not presented in accordance with, nor are they a substitute for U.S. generally accepted accounting principles, or GAAP. These measures include: non-GAAP gross profit; non-GAAP operating expense; non-GAAP operating earnings; non-GAAP operating earnings margin; non-GAAP earnings before taxes; non-GAAP net earnings; non-GAAP net earnings per diluted sharer, non-GAAP dilutive shares; and non-GAAP EBITDA. We are providing a reconciliation above of each non-GAAP financial measure used in this earnings release to the most directly comparable GAAP financial measure. We are unable to provide without unreasonable effort a reconciliation of non-GAAP guidance measures to the corresponding GAAP measures on a forward-looking basis due to the potential significant variability and limited visibility of the excluded items discussed.

We utilize a number of different financial measures, both GAAP and non-GAAP, in analyzing and assessing the overall performance of our business, in making operating decisions, and forecasting and planning for future periods. We consider the use of the non-GAAP measures to be helpful in assessing the performance of the ongoing operation of our business by excluding unusual and one-time costs. We believe that disclosing non-GAAP financial measures provides useful supplemental data that allows for greater transparency in the review of our financial and operational performance. We also believe that disclosing non-GAAP financial measures provides useful information to investors and others in understanding and evaluating our operating results and future prospects in the same manner as management and in comparing financial results across accounting periods and to those of peer companies.

Non-GAAP measures include the following items:

Amortization of intangible assets: We do not acquire businesses and assets on a predictable cycle. The amount of purchase price allocated to intangible assets and the term of amortization can vary significantly and are unique to each acquisition or purchase. We believe that excluding amortization of intangible assets allows the users of our financial statements to better review and understand the historic and current results of our operations, and also facilitates comparisons to peer companies.

Purchase price accounting charges to cost of revenues: We may incur charges to cost of revenues as a result of acquisitions. We believe that excluding these charges allows the users of our financial statements to better understand the historic and current cost of our products, our gross margin, and also facilitates comparisons to peer companies.

Restructuring charges: We incur restructuring charges that result from events, which arise from unforeseen circumstances and/or often occur outside of the ordinary course of our on-going business. Although these events are reflected in our GAAP financials, these unique transactions may limit the comparability of our on-going operations with prior and future periods.

Acquisition and integration related costs: We incur expenses or benefits with respect to certain items associated with our acquisitions, such as transaction costs, changes in fair value of acquisition related hedges, changes in the fair value of contingent consideration liabilities, gain or expense on settlement of pre-existing relationships, etc. We exclude such expenses or benefits as they are related to acquisitions and have no direct correlation to the operation of our on-going business. We also incur expenses or benefits with respect to certain items associated with our acquisitions, such as integration costs relating to acquisitions for any costs incurred prior to closing and up to 12 months after the closing date of the acquisition.

Impairment charges: We may incur impairment charges that result from events, which arise from unforeseen circumstances and/or often occur outside of the ordinary course of our on-going business and such charges may limit the comparability of our on-going operations with prior and future periods.

Other non-operational costs: Certain items may be non-recurring, unusual, infrequent and directly related to an event that is distinct and non-reflective of the Company's ongoing business operations. These may include such items as non-ordinary course litigation, legal settlements, inventory write-downs for discontinued products, cost of facilities no longer in use, extinguishment of debt and hedge costs, environmental settlements, governmental settlements including tax settlements, and other items of similar nature

Convertible notes non-cash interest expense: We issued convertible notes in June 2020 at a discount related to the conversion feature of the notes and capitalized certain costs related to the issuance of these notes. The discount and capitalized issuance costs are amortized into interest expense over the term of the convertible notes. The amortization recognized for the convertible notes will be greater than the cash interest payments for the notes. We believe that excluding the convertible notes non-cash interest expense allows the users of our financial statements to better understand the historic and current results of our operations. This also facilitates comparisons to peer companies.

Non-operational tax adjustments: Certain tax items may be non-recurring, unusual, infrequent and directly related to an event that is distinct and non-reflective of the Company's normal business operations. These may include such items as the retroactive impact of significant changes in tax laws, including changes to statutory tax rates and one-time tax charges.

Tax effects of operating earnings adjustments: We apply our non-GAAP adjustments to the GAAP pretax income to calculate the non-GAAP effective tax rate. This application of our non-GAAP effective tax rate excludes any discrete items, as defined in the guidance for accounting for income taxes in interim periods, or any other non-operational tax adjustments.

Dilution offset from convertible notes hedge transaction: In connection with the issuance of the Company's Convertible Senior Unsecured Notes (the Convertible Notes) in June 2020, the Company entered into convertible note hedge transactions (the Hedge Transactions) to reduce the potential dilutive effect on common shares upon the eventual conversion of the Convertible Notes. GAAP diluted shares outstanding includes the incremental dilutive shares from the Company's Convertible Notes. Under GAAP, the anti-dilutive impact of the Company has GAAP net income, the non-GAAP diluted shares count includes the anti-dilutive impact of the Company's Hedge Transactions, which reduces the potential dilution that otherwise would occur upon conversion of the Company's Convertible Notes. We believe non-GAAP diluted shares is a useful non-GAAP metric because it provides insight into the offsetting economic effect of the Hedge Transactions against potential conversion of the Convertible Notes.



Solutions in Sight®